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Summary
Oncogenic osteomalacia secondary to glomus tumor is extremely rare. Localization of causative tumors is critical as
surgical resection can lead to a complete biochemical and clinical cure. We present a case of oncogenic osteomalacia
treated with resection of glomus tumor. A 39-year-old woman with a history of chronic sinusitis presented with chronic
body ache and muscle weakness. Biochemical evaluation revealed elevated alkaline phosphatase hypophosphatemia,
increased urinary phosphate excretion, low calcitriol, and FGF23 was unsuppressed suggestive of oncogenic osteomalacia.
Diagnostic studies showed increase uptake in multiple bones. Localization with MRI of paranasal sinuses revealed a
sinonasal mass with concurrent uptake in the same area on the octreotide scan. Surgical resection of the sinonasal
mass was consistent with the glomus tumor. The patient improved both clinically and biochemically postoperatively.
Along with the case of oncogenic osteomalacia secondary to a glomus tumor, we have also discussed in detail the recent
development in the diagnosis and management of oncogenic osteomalacia.

Learning points:
•• Tumor-induced osteomalacia is a rare cause of osteomalacia caused by the secretion of FGF23 from
mesenchymal tumors.
•• Mesenchymal tumors causing TIO are often difficult to localize and treat.
•• Resection of the tumor can result in complete resolution of biochemical and clinical manifestations in a very short
span of time.
•• Glomus tumor can lead to tumor induced osteomalacia and should be surgically treated.

Background
Tumor-induced osteomalacia (TIO), also known
as oncogenic osteomalacia, is a rare and acquired
paraneoplastic syndrome. TIO is characterized by
hypophosphatemia, increased urinary phosphate
excretion and low calcitriol levels due to FGF23,
secreted by the tumor (1). This ultimately results in
hypophosphatemic osteomalacia and can have variable
manifestations ranging from diffuse musculoskeletal
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pain to bone fractures. Despite obvious diagnosis among
patients presenting with aforementioned clinical and
biochemical findings, the subsequent localization
of mesenchymal tumor often remains challenging.
This results in a significant delay in the diagnosis and
treatment of these patients. Herein, we are presenting a
case of TIO caused by glomus tumor localized in the right
sinus cavity.
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Case presentation
A 39-year-old woman with a past medical history of
chronic sinusitis presented with progressively worsening
generalized body pain and muscle weakness of 8 months
duration. Patient was afebrile and hemodynamically
stable on presentation. On musculoskeletal examination,
she had decreased muscle strength in bilateral upper and
lower extremities. Rest of the physical examination was
unremarkable except for the presence of a congenital cleft
palate.

Investigation
Laboratory workup revealed elevated alkaline phosphatase
603 U/L (44–147 U/L), low serum phosphate 1.5 mg/
dL (3.5–5.0 mg/dL), normal serum calcium 8.9 mg/dL
(8.3–10.4 mg/dL), normal 25-hydroxyvitamin D 32 ng/dL
(30–100 ng/dL), elevated 1,25-dihydroxyvitamin D 62 g/
mL (20–45 pg/mL), elevated intact PTH level 99.01 pg/mL
(8–74 pg/mL), high normal 24 h urinary phosphate levels
1100 mg/dL, and elevated FGF23 level 128 RU/mL (<108
RU/mL). Complete blood count was within normal range.
This is summarized in Table 1. Bone densitometry revealed
a normal bone density and parathyroid scintigraphy was
negative for adenoma. Considering clinical symptoms
along with biochemical evidence of phosphate wasting
as confirmed by low TRP and an unsuppressed FGF23
levels, a decision to consider oncogenic osteomalacia as
an underlying cause for patients’ symptoms was pursued.
Whole-body bone scan demonstrated an increased
radiotracer uptake in the elbows, spine, sacroiliac
Table 1
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joints, knees, ankles and multiple ribs suggestive of an
inflammatory process. MRI of paranasal sinuses revealed
a large soft tissue mass completely occupying the right
frontal, ethmoid, maxillary and sphenoid sinuses and
expanding into the right nasal cavity suggestive of
sinonasal polyposis (Fig. 1). 99mTc-Octreotide scan showed
an abnormal area of increased uptake in the nasopharynx.

Treatment
The sinonasal mass was resected and immune histochemical
studies showed positive S100 and negative CD34, CK, SMA,
LCA, SAL4 and Caldesmin suggestive for glomus tumor.
Ki67 index was 3–4%.

Outcome and follow-up
Postoperatively, phosphate levels normalized to 3 mg/
dL on day 7. At 3 months follow-up visit, FGF23 was 10
RU/mL, PTH was 40 pg/mL, total calcium was 8.9 mg/dL,
phosphate was 3.4 mg/dL, and 25-hydroxyvitamin D 32
ng/mL, which were all within normal limits.

Discussion
Oncogenic osteomalacia, also known as 'tumor-induced
osteomalacia (TIO)' is a paraneoplastic syndrome resulting
in biochemical and pathological changes similar to
hypophosphatemic rickets (1). Glomus tumor as a cause
of tumor-induced osteomalacia is an extremely rare entity
with only a limited number of published case reports.

Laboratory results.

Laboratory test

Plasma glucose
Serum calcium, total
Serum phosphate
Serum albumin
Blood urea nitrogen
Serum creatinine
Serum aspartate transaminases
Serum alanine transaminases
Serum alkaline phosphatase
Intact parathyroid hormone
25-hydroxy vitamin D
1,25-dihydroxy vitamin D
Phosphate in 24 h urine (concentration mg/dL or mEq/L)
Creatinine in 24 h urine (concentration mg/dL)
24 h urine calcium (concentration mg/dL)
Urine volume
Post-operative phosphate
FGF23

Level

Reference range

104 mg/dL
8.9 mg/dL
1.5 mg/dL or 0.97 mEq/L
4.2 mg/dL
10 mg/dL
0.9 mg/dL
23 U/L
27 U/L
603 IU/L
99.01 pg/mL
32 ng/mL
62 pg/mL
1100 mg/day (88 mg/dl or 56.77 mEq/L)
614 mg/day (49.1 mg/dL)
165 mg/day (13.2 mg/dL)
1250 mL (12.5 dL)
2.8 mg/dL
128 RU/mL

74–90 mg/dL
8.3–10.4 mg/dL
3.5–5.0 mg/dL
3.4–5.4 mg/dL
6–24 ng/dL
0.60–1.10 mg/dL
8–48 U/L
7–45 U/L
44–147 IU/L
8.0–74.0 pg/mL
20–80 ng/mL
20–45 pg/mL
360–1600 mg/day
500–200 mg/day
100–250 mg/day
3.5–5.0 mg/dL
< or = 108 RU/mL
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Figure 1
MRI of paranasal sinus revealed a large soft tissue mass completely
occupying the right frontal, ethmoid, maxillary and sphenoid sinuses and
expanding in to the right nasal cavity and deviating nasal septum towards
the left side.

It is a mesenchymal tumor composed of modified smooth
muscle cells arising from the glomus body, a specialized
arteriovenous anastomosis that regulates heat in the
skin. Glomus tumor is predominantly cutaneous, most
commonly in the subungual region of the finger but can
occur anywhere in the body, however, they are usually
benign with very rare malignant variability (2).
The mesenchymal tumors secrete fibroblast growth
factor 23 (FGF23). Excess FGF23 acts via FGF receptor
1 (FGFR1) on the kidneys and results in the decreased
reabsorption of phosphate and decreased production
of 1,25-dihydroxy vitamin D ultimately resulting in
hypophosphatemia (3). This results in the biochemical
finding of hypophosphatemia, low 1,25-dihydroxy vitamin
D and increased urinary phosphate excretion along with
the clinical symptoms of osteomalacia characterized by
bone and muscle pain, muscle weakness, and fractures (4).
In the majority of cases of oncogenic osteomalacia, FGF23
is high but it can also be inappropriate in the normal
range (5). In our patient, FGF23 was inappropriately high,
in the presence of concomitant hypophosphatemia and
increased urinary phosphate excretion which led us to
consider oncogenic osteomalacia as an underlying cause.
As simultaneous plasma and urine values are more accurate
when assessing fractional excretion of any molecule,
particularly ones that can vary throughout the day, TmP/
GFR could not be successfully calculated in our case as we
only had 24 h urine phosphate and creatinine values but not
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spot urine data. Nevertheless, a successful surgical outcome
as suggested by rapid resolution of clinical symptoms,
increase in phosphate level and drop in FGF23 levels after
surgery retrospectively supports oncogenic osteomalacia
as the underlying cause in our patient. Typically, these
patients have normal PTH and calcium levels, however,
with prolonged disease and treatment, they can develop
secondary hyperparathyroidism resulting in elevated PTH
levels (6).
Once the diagnosis is established, detection and
localization of the causative tumor are the most important
next step. As these mesenchymal tumors tend to be small in
size, have an indolent course and are mysteriously hidden
in unusual places, these are often difficult to localize on
conventional imaging modalities (7). Imaging modalities
involving whole-body MRI, 18F-FDG-PET/CT, octreotide
scan, and 68Ga-DOTATATE PET/CT have been successfully
used to localize these tumors. One study compared 18FFDG PET/CT and 68Ga DOTATATE PET/CT and suggested
68Ga DOTATATE PET/CT be superior to 18F-FDG PET/
CT in diagnosing TIO and recommended to consider
68Ga DOTATATE PET/CT as an initial diagnostic test for
localization studies (8, 9). Despite these approaches, the
success rates of tumor identification remain to be 65–80%.
Furthermore, due to this difficulty in tumor detection,
there is often a significant delay between symptom onset
and treatment of TIO (10).
Following localization of the tumor, the choice of
treatment is the surgical resection of the tumor with a
clear surgical margin to prevent tumor recurrence. FGF23
has a short half-life of approximately 45 min and hence
surgical cure can be determined by a drop in FGF23 level
postoperatively (11). Serum phosphate levels normalize
between 5 and 10 post-operative days and the majority of
patients feel better within days to weeks of tumor removal
resulting in rapid and complete biochemical and clinical
cures (7). Although the bone starts to heal immediately, it
may vary depending on the severity of the disease process
and may take years for significant recovery. Although late
recurrence has been reported, it is extremely rare and can
be seen with malignant mesenchymal tumors (12, 13).
When the tumor cannot be localized or is not
surgically resectable, medical therapy is considered.
Historically, phosphate and vitamin D supplementation
used to be the main stay of treatment, however, recently
Burosumab has become the preferred form of therapy and
based on ongoing open-label Phase 2 study, it was FDA
approved in June 2020 for use among patients with TIO.
It has been shown to improve bone turnover markers and
parameters of osteomalacia on bone biopsy. Furthermore,
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it also improves ambulation, reduces pain and results
in sustained normalization of phosphate levels among
treated patients (14). The goal of treatment among these
patients with Burosumab or with phosphate and vitamin
D supplementation is to achieve a serum phosphate in the
lower end of the age-appropriate normal range.
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